366 related articles for article (PubMed ID: 7896207)
1. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
Bowen DT; Culligan D; Beguin Y; Kendall R; Willis N
Leukemia; 1994 Jan; 8(1):151-5. PubMed ID: 8289479
[TBL] [Abstract][Full Text] [Related]
4. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
[TBL] [Abstract][Full Text] [Related]
5. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
Daschner M; Mehls O; Schaefer F
Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
[TBL] [Abstract][Full Text] [Related]
6. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
8. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
9. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
10. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.
Arndt U; Kaltwasser JP; Gottschalk R; Hoelzer D; Möller B
Ann Hematol; 2005 Mar; 84(3):159-66. PubMed ID: 15565327
[TBL] [Abstract][Full Text] [Related]
11. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
[TBL] [Abstract][Full Text] [Related]
12. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
13. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
Wang W; Zhang MH; Yu Y; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
[TBL] [Abstract][Full Text] [Related]
14. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
[TBL] [Abstract][Full Text] [Related]
15. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis.
Bowen D; Ehmer B; Neubert P; Lewis T; Jacobs A
Exp Hematol; 1991 Aug; 19(7):613-6. PubMed ID: 1716588
[TBL] [Abstract][Full Text] [Related]
16. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
[TBL] [Abstract][Full Text] [Related]
17. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome.
Metzgeroth G; Rosée PL; Kuhn C; Schultheis B; Dorn-Beineke A; Hehlmann R; Hastka J
Eur J Haematol; 2007 Jul; 79(1):8-16. PubMed ID: 17532764
[TBL] [Abstract][Full Text] [Related]
18. [Value of analyzing reticulocyte subpopulations in polycythemia].
Ataulfo González F; Bermejo A; Sánchez J; Anguita E; Villegas A
Sangre (Barc); 1997 Oct; 42(5):383-6. PubMed ID: 9424738
[TBL] [Abstract][Full Text] [Related]
19. Assessment of erythropoiesis activity during hemodialysis therapy by soluble transferrin receptor levels and ferrokinetic measurements.
Lorenzo JD; Rodríguez MM; Martín SS; Romo JM
Am J Kidney Dis; 2001 Mar; 37(3):550-6. PubMed ID: 11228179
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron.
Goodnough LT; Marcus RE
Vox Sang; 1998; 75(2):128-33. PubMed ID: 9784666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]